Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives $90.43 Consensus PT from Brokerages

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have been given a consensus recommendation of “Moderate Buy” by the nine ratings firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $100.25.

ESTA has been the topic of a number of recent analyst reports. Canaccord Genuity Group set a $105.00 price objective on Establishment Labs in a research report on Thursday. JPMorgan Chase & Co. upped their target price on Establishment Labs from $84.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday. BTIG Research raised their price target on Establishment Labs from $96.00 to $103.00 and gave the company a “buy” rating in a report on Thursday. Needham & Company LLC lifted their price target on Establishment Labs from $86.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Mizuho boosted their price objective on Establishment Labs from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th.

Establishment Labs Stock Performance

Establishment Labs stock opened at $77.42 on Friday. The firm’s 50 day simple moving average is $86.43 and its 200 day simple moving average is $74.25. The company has a current ratio of 2.96, a quick ratio of 1.91 and a debt-to-equity ratio of 16.82. The firm has a market capitalization of $2.28 billion, a PE ratio of -59.10 and a beta of 1.07. Establishment Labs has a 1-year low of $33.35 and a 1-year high of $97.59.

Establishment Labs (NASDAQ:ESTA) last posted its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.05). The firm had revenue of $67.54 million during the quarter, compared to analysts’ expectations of $65.79 million. Establishment Labs had a negative return on equity of 205.79% and a negative net margin of 15.82%.The business’s revenue for the quarter was up 31.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.57) earnings per share. As a group, analysts expect that Establishment Labs will post -1.07 earnings per share for the current fiscal year.

More Establishment Labs News

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: JPMorgan raised its price target on Establishment Labs from $84 to $95 and maintained an Overweight rating, implying substantial upside from the current trading level. Benzinga analyst report
• Positive Sentiment: BTIG increased its price target from $96 to $103 and reiterated a Buy rating, while Needham lifted its target from $86 to $95 and also maintained a Buy rating. These revisions suggest analysts remain optimistic about the company’s growth prospects. The Fly analyst report
• Positive Sentiment: Establishment Labs reported quarterly revenue of $67.54 million, exceeding the $65.79 million analyst estimate and increasing 31.7% year over year. The company also projected 2026 revenue of $269 million to $271 million, above the $267.5 million consensus estimate. Zacks quarterly results report
• Neutral Sentiment: Management indicated that minimally invasive procedures now account for approximately 15% of sales, highlighting potential for longer-term market expansion, but investors may remain focused on the company’s path to profitability. Seeking Alpha revenue outlook report
• Negative Sentiment: The company reported a second-quarter loss of $0.39 per share, wider than the $0.34 expected loss, though the result improved from a $0.57 loss in the year-ago quarter. The earnings miss, continued negative margins, and lack of profitability are likely weighing on the shares. MarketBeat earnings report

Institutional Trading of Establishment Labs

Several institutional investors and hedge funds have recently made changes to their positions in the stock. KBC Group NV purchased a new position in Establishment Labs in the first quarter worth $28,000. Quarry LP purchased a new position in shares of Establishment Labs in the 3rd quarter worth about $34,000. Kestra Advisory Services LLC bought a new position in shares of Establishment Labs during the 4th quarter valued at about $47,000. Osaic Holdings Inc. raised its holdings in shares of Establishment Labs by 900.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after buying an additional 1,800 shares in the last quarter. Finally, State of Wyoming bought a new stake in Establishment Labs in the 2nd quarter worth approximately $87,000. Hedge funds and other institutional investors own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.